Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via F. Sforza 35, 20122, Milan, Italy.
University of Milan, Milan, Italy.
Eur J Nucl Med Mol Imaging. 2019 Feb;46(2):280-287. doi: 10.1007/s00259-018-4182-1. Epub 2018 Oct 21.
The disease course of multiple sclerosis (MS) is unpredictable, and reliable prognostic biomarkers are needed. Positron emission tomography (PET) with β-amyloid tracers is a promising tool for evaluating white matter (WM) damage and repair. Our aim was to investigate amyloid uptake in damaged (DWM) and normal-appearing WM (NAWM) of MS patients, and to evaluate possible correlations between cerebrospinal fluid (CSF) β-amyloid (Aβ) levels, amyloid tracer uptake, and brain volumes.
Twelve MS patients were recruited and divided according to their disease activity into active and non-active groups. All participants underwent neurological examination, neuropsychological testing, lumbar puncture, brain magnetic resonance (MRI) imaging, and F-florbetapir PET. Aβ levels were determined in CSF samples from all patients. MRI and PET images were co-registered, and mean standardized uptake values (SUV) were calculated for each patient in the NAWM and in the DWM. To calculate brain volumes, brain segmentation was performed using statistical parametric mapping software. Nonparametric statistical analyses for between-group comparisons and regression analyses were conducted.
We found a lower SUV in DWM compared to NAWM (p < 0.001) in all patients. Decreased NAWM-SUV was observed in the active compared to non-active group (p < 0.05). Considering only active patients, NAWM volume correlated with NAWM-SUV (p = 0.01). Interestingly, CSF Aβ concentration was a predictor of both NAWM-SUV (r = 0.79; p = 0.01) and NAWM volume (r = 0.81, p = 0.01).
The correlation between CSF Aβ levels and NAWM-SUV suggests that the predictive role of β-amyloid may be linked to early myelin damage and may reflect disease activity and clinical progression.
多发性硬化症(MS)的病程不可预测,因此需要可靠的预后生物标志物。正电子发射断层扫描(PET)结合β-淀粉样蛋白示踪剂是评估白质(WM)损伤和修复的有前途的工具。我们的目的是研究 MS 患者的受损白质(DWM)和正常外观白质(NAWM)中的淀粉样蛋白摄取情况,并评估脑脊液(CSF)β-淀粉样蛋白(Aβ)水平、淀粉样蛋白示踪剂摄取与脑容量之间的可能相关性。
招募了 12 名 MS 患者,并根据其疾病活动度分为活动期和非活动期两组。所有参与者均接受了神经学检查、神经心理学测试、腰椎穿刺、脑磁共振成像(MRI)和 F-氟比他滨 PET。所有患者均测定 CSF 中的 Aβ 水平。对 MRI 和 PET 图像进行配准,并计算每位患者的 NAWM 和 DWM 的平均标准化摄取值(SUV)。为了计算脑容量,使用统计参数映射软件进行脑分割。进行了组间比较的非参数统计分析和回归分析。
我们发现所有患者的 DWM 比 NAWM 的 SUV 低(p < 0.001)。与非活动组相比,活动组的 NAWM-SUV 降低(p < 0.05)。仅考虑活动组患者,NAWM 体积与 NAWM-SUV 相关(p = 0.01)。有趣的是,CSF Aβ 浓度可预测 NAWM-SUV(r = 0.79;p = 0.01)和 NAWM 体积(r = 0.81,p = 0.01)。
CSF Aβ 水平与 NAWM-SUV 之间的相关性表明,β-淀粉样蛋白的预测作用可能与早期髓鞘损伤有关,并可能反映疾病活动度和临床进展。